Anileridine phosphate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for anileridine phosphate and what is the scope of patent protection?

Anileridine phosphate is the generic ingredient in one branded drug marketed by Merck and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for anileridine phosphate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	4
DailyMed Link:	anileridine phosphate at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for anileridine phosphate

N01AH	Opioid anesthetics
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

US Patents and Regulatory Information for anileridine phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	LERITINE	anileridine phosphate	INJECTABLE;INJECTION	010520-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Anileridine Phosphate: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is anileridine phosphate and how does it sit in the market?

Anileridine phosphate is the phosphate salt form of anileridine, an opioid analgesic. Commercialization and revenue potential depend less on the salt form and more on the active pharmaceutical ingredient (API) anileridine and the regulatory status of that API in each territory.

From a market-structure standpoint, opioid pain therapeutics tend to follow three forces that shape financial outcomes for individual molecules:

• Regulatory access and controlled-substance scheduling that constrain prescribing and distribution.
• Formulation and safety profile that determine whether clinicians and payers adopt the drug versus alternatives.
• Competition from newer analgesics and opioid stewardship policies that reduce volume growth for older opioid chemotypes.

In practice, for anileridine-containing products, the financial trajectory is typically defined by whether regulators sustain access and whether generic competition appears, rather than by patent-led exclusivity alone.

What market dynamics affect sales and pricing?

1) Controlled-substance friction and prescriber adoption

Anileridine is an opioid. Opioid products in major markets usually face:

• Tight distribution controls and pharmacy-level dispensing constraints
• Higher scrutiny under opioid prescribing guidelines
• Contracting controls and utilization management in some payer environments

These factors reduce the elasticity of demand and make sales growth dependent on institutional adoption rather than retail pull.

2) Substitution risk from established opioids

Opioid analgesics already have established treatment pathways. Substitution pressure is driven by:

• Availability of widely used comparator opioids with entrenched formularies
• Differences in perceived safety/tolerability that affect switch rates
• Hospital and long-term care formulary preferences

For anileridine phosphate, the dominant commercial risk is rapid therapeutic substitution if clinicians do not view the drug as clearly superior in safety, efficacy, route of administration, or patient-relevant outcomes.

3) Patent life cycle and generics

For a salt form, the market outcome depends on:

• Whether the API has active exclusivity in a given jurisdiction
• Whether there are generic salts or a generic anileridine supply that bypasses salt-specific IP
• Whether the product is sold as a stand-alone branded product or bundled into generic channels

In older opioid molecules, the historical pattern is early erosion of branded pricing when generic entry becomes feasible.

How would the financial trajectory typically evolve across the product life cycle?

Stage A: Launch or re-entry phase

Revenue drivers usually include:

• Initial formulary inclusion in limited channels
• Hospital-specific uptake if adopted for specific protocols
• Distribution ramp that reflects controlled-substance licensing timelines

Cost drivers rise in parallel:

• Regulatory maintenance costs
• Controlled logistics and compliance
• Pharmacovigilance and ongoing safety obligations common to opioids

Net effect: early financial results can look stable or volatile depending on whether adoption occurs in major clinical centers versus niche markets.

Stage B: Growth plateau

Growth typically plateaus when:

• Formularies either lock in or exclude the product
• Competitors already cover most opioid use cases
• Prescribing restrictions reduce incremental volume

For anileridine phosphate, plateau behavior is common when there is no major clinical differentiator versus opioids already in routine use.

Net effect: sales stop expanding at branded-like rates; pricing power compresses.

Stage C: Competitive erosion

Financial deterioration usually tracks:

• Generic entry or parallel imports
• Contracting pressure from payers
• Ongoing opioid stewardship tightening

For opioids, volume can remain steady while price per unit declines, driving margin compression even if total use does not collapse.

Stage D: Decline or withdrawal

A decline can follow:

• Reduced regulatory approvals or limited renewals
• Safety signal scrutiny in opioid classes
• Commercial withdrawal due to low profitability in controlled channels

What does the broader opioid regulatory environment imply for anileridine phosphate economics?

Opioid stewardship has shifted the economics of opioid products in two ways:

1. Lower total addressable patient volume through guideline adherence and utilization review
2. Higher compliance costs tied to prescribing monitoring, documentation, and risk management

Even if an opioid remains available, the economics often become “maintenance mode” rather than “expansion mode,” especially for molecules that lack differentiated clinical positioning.

How can investors and R&D teams frame the financial trajectory in KPIs?

Given the dynamics above, the most decision-relevant KPIs for anileridine phosphate are not only top-line sales but channel mechanics:

• Formulary status (hospital and outpatient coverage)
• Utilization rate (scripts per eligible patient or defined population)
• Net price vs list price (contracting and discounting intensity)
• Unit economics (gross margin after controlled logistics and compliance)
• Share against comparator opioids in key specialties

These KPIs map directly to how controlled-substance economics play out.

Is there evidence of patent-driven or generic-driven revenue behavior?

No patent-to-revenue mapping can be stated without specific, territory-level exclusivity status and product listing history for anileridine phosphate. For opioid molecules generally, branded revenue typically collapses once generics or alternative opioids establish coverage. For salt forms specifically, salt-specific exclusivity rarely prevents generic bypass if the API is not protected.

Business implication: For anileridine phosphate, the financial trajectory is more likely to be dominated by regulatory access and generic competition than by salt-specific IP.

What scenarios best describe likely financial outcomes?

Even without territory-specific financial disclosures, the market mechanics support three repeatable outcome profiles:

Outcome profile	Market condition	Sales pattern	Margin pattern	Primary risk
Niche steady	Limited formulary access but continued availability	Low but stable	Moderate-to-low	Therapeutic substitution
Contract-driven decline	Broader availability but payer/hospital contracting tightens	Flat-to-down volumes	Margin compression	Net price erosion
Rapid erosion	Generic substitution becomes feasible quickly	Downward	Low	Loss of branded relevance

For opioids, the “contract-driven decline” profile is common because usage can persist while pricing power erodes.

What time horizons matter for anileridine phosphate?

Opioid commercial trajectories often pivot on:

• Annual formulary cycles
• Multi-year generic entry and re-supply decisions
• Regulatory renewal windows for controlled-substance distribution and labeling

As a result, financial outlook typically changes in step-functions around these milestones rather than drifting continuously.

---

Key Takeaways

• Anileridine phosphate is an opioid salt product; its commercial trajectory is dominated by controlled-substance logistics, formulary adoption, opioid stewardship, and substitution by other opioids.
• Financial outcomes typically move from initial access ramp to plateau, followed by pricing and margin compression under contracting and generic pressure.
• For decision-making, track formulary status, utilization, net price, and unit economics, not just list-price assumptions.
• Without confirmed territory-specific exclusivity and listing history, the safest business read is that generic and contracting dynamics will outweigh salt-specific IP in determining financial trajectory.

FAQs

1. Does anileridine phosphate revenue depend on the salt form or the API?
   Revenue hinges primarily on the API anileridine regulatory and exclusivity position; salt forms usually do not prevent generic bypass when the API is accessible.

2. What is the biggest commercial headwind for opioid molecules like anileridine?
   Therapeutic substitution and opioid prescribing restrictions that limit incremental demand and compress net pricing.

3. How do generics typically affect opioid product financials?
   They usually drive net price declines and margin erosion; volume may soften or remain partly stable depending on coverage and switching behavior.

4. What KPI best predicts whether an opioid product can sustain profitability?
   Net price and gross margin after contracting, linked to utilization in covered channels.

5. What milestone timing most often changes the financial outlook for opioid products?
   Formulary cycles, generic entry windows, and regulatory renewal points that alter access and distribution feasibility.

References

[1] (No citations available from the provided context.)